Minimal functional β-cell mass in intraportal implants that reduces glycemic variability in type 1 diabetic recipients.

ABSTRACT:

Objective

Previous work has shown a correlation between β-cell number in cultured islet cell grafts and their ability to induce C-peptide secretion after intraportal implantation in C-peptide-negative type1 diabetic patients. In this cross-sectional study, we examined the minimal functional β-cell mass (FBM) in the implant that induces metabolic improvement.

Research design and methods

Glucose clamps assessed FBM in 42 recipients with established implants. C-peptide release during each phase was expressed as percentage of healthy control values. Its relative magnitude during a second hyperglycemic phase was most discriminative and therefore selected as a parameter to be correlated with metabolic effects.

Results

Recipients with functioning β-cell implants exhibited av

SUBMITTER: Gillard P 

PROVIDER: S-EPMC3816855 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature